Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 18 2024
0mins
Source: NASDAQ.COM
Overview of Invesco Biotechnology & Genome ETF (PBE): The PBE ETF, launched in 2005 and managed by Invesco, focuses on the Healthcare - Biotech sector, offering low-cost, diversified exposure with an annual operating expense of 0.58% and a current asset value of over $271 million.
Performance and Alternatives: PBE has shown an 8.14% return year-to-date and a 20.51% increase over the past year, but it carries a higher risk profile with a beta of 0.80; investors may also consider alternatives like SPDR S&P Biotech ETF (XBI) and iShares Biotechnology ETF (IBB).
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GILD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to rise
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 130.500
Low
105.00
Averages
137.88
High
154.00
Current: 130.500
Low
105.00
Averages
137.88
High
154.00
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Livdelzi/Lyvdelzi, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada for PrEP, and others. It also sells and distributes authorized generic versions of Epclusa and Harvoni in the United States through its subsidiary, Asegua Therapeutics LLC. It has control on anitocabtagene autoleucel (anito cel), an investigational BCMA-directed CAR T cell therapy for multiple myeloma. It operates in over 35 countries worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gilead Acquires Tubulis for $3.15B to Enhance Oncology Portfolio
- Acquisition Scale: Gilead Sciences completed the acquisition of Tubulis GmbH for $3.15 billion in upfront payments, with potential milestone payments of up to $1.85 billion, significantly enhancing its oncology portfolio through this strategic move.
- Innovation Center Establishment: Following the acquisition, the Tubulis team will remain in Munich to establish 'The Tubulis ADC Innovation Center,' focusing on research, manufacturing, and clinical development of antibody-drug conjugates, thereby enhancing Gilead's R&D capabilities in cancer treatment.
- Clinical Asset Integration: Tubulis' lead candidate TUB-040 is currently being evaluated for platinum-resistant ovarian and non-small cell lung cancers, and by integrating these clinical assets, Gilead aims to address significant treatment gaps for patients with challenging solid tumors.
- Market Leadership: This acquisition not only solidifies Gilead's leadership position in oncology innovation but also drives the advancement of transformative cancer treatments by combining existing infrastructure with Tubulis' innovative platform, addressing unmet medical needs.
See More
U.S. Stocks Rise as Hopes for Iran Peace Deal Increase
- Strong U.S. Market Performance: The S&P 500 rose by 0.4%, the Dow Jones increased by 0.6%, and the Nasdaq gained 0.2%, marking the longest weekly gain streak since 2023, indicating increased investor confidence in risk assets amid hopes for a U.S.-Iran peace deal.
- Active ETF Market: The SPDR S&P 500 ETF and Invesco QQQ Trust both rose by 0.4%, while the Dow Jones Industrial Average ETF increased by 0.7%, reflecting optimistic sentiment towards major indices, particularly ahead of the upcoming three-day weekend.
- Oil Prices Edge Up: International Brent crude futures added 0.9% to close at $103.54 per barrel, while West Texas Intermediate crude rose about 0.3%, reflecting market hopes for a resolution to the Iran conflict, although still below earlier peaks this week.
- New Fed Chair Sworn In: Kevin Warsh was officially sworn in as the 17th Chair of the Federal Reserve, with market expectations regarding his policy direction likely to influence future monetary policy and economic trends, especially in the context of the current economic recovery.
See More
Gilead Secures Accelerated Approval for Hepcludex
- FDA Accelerated Approval: Gilead Sciences' Hepcludex has received accelerated approval from the FDA, becoming the first treatment for chronic hepatitis delta virus infection in the U.S., addressing a long-standing gap in care for approximately 40,000 to 80,000 patients, which is expected to significantly enhance their quality of life.
- Clinical Trial Data Support: The FDA's decision was heavily informed by data from the MYR301 multi-center Phase 3 clinical trial, which demonstrated that the percentage of participants with completely undetectable viral levels increased from 20% at week 48 to 50% by week 144, confirming the drug's efficacy over time.
- Positive Market Reaction: Following the FDA approval, Gilead's stock price surged nearly 3%, poised for its best day in about three months, reflecting strong market anticipation for the new therapy and a recovery in investor confidence, with a 29% increase in stock price over the past year.
- Global Market Presence: While newly approved in the U.S., the 2 mg dose of Hepcludex has already been available in the European Economic Area and other global markets, indicating Gilead's strategic positioning and commitment to addressing chronic liver disease treatment worldwide.
See More
Gilead Receives FDA Approval for Chronic HDV Treatment
- FDA Accelerated Approval: Gilead Sciences announced that its Hepcludex (bulevirtide-gmod) 8.5 mg has received accelerated approval from the FDA, becoming the first treatment for chronic hepatitis delta virus (HDV) infection in the U.S., addressing a significant unmet medical need.
- Clinical Trial Results: In the pivotal MYR301 Phase 3 trial, Hepcludex demonstrated statistically significant improvements in HDV RNA reduction and alanine aminotransferase (ALT) normalization at Week 48 compared to the control group, indicating its efficacy.
- Patient Impact: Chronic HDV is considered the most severe form of viral hepatitis, and the FDA approval provides a new treatment option for approximately 40,000 to 80,000 HDV patients in the U.S., potentially significantly improving their quality of life and disease management.
- Future Research Commitment: Gilead has committed to conducting a confirmatory long-term outcomes study to verify the clinical benefits of Hepcludex, ensuring continued approval, which reflects the company's strong commitment to addressing this serious disease.
See More
FDA Approves Gilead's Hepcludex for HDV Infection
- First HDV Treatment: Gilead Sciences' Hepcludex (bulevirtide) has received FDA approval as the first-ever therapy for chronic hepatitis delta virus (HDV) infection, marking a significant breakthrough in liver disease treatment.
- Clinical Trial Success: The approval is based on phase 3 trial results showing that patients receiving Hepcludex had significantly better combined responses compared to those receiving delayed treatment, indicating its clinical efficacy.
- Special Drug Designations: Hepcludex has received Breakthrough Therapy and Orphan Drug designations, which not only expedited its approval process but also reflects the FDA's recognition of its potential in treating HDV infections.
- International Market Outlook: Approved in the EU in 2020 and expected to launch in Canada in 2025, Hepcludex demonstrates broad application potential in global markets, which could lead to substantial revenue growth for Gilead.
See More
WHO Raises Ebola Outbreak Risk Level in DRC to Very High
- Risk Level Increase: The WHO has raised the risk assessment for the Bundibugyo Ebola strain in the Democratic Republic of Congo to 'very high', indicating a significant potential for rapid virus spread that threatens national public health.
- Case Statistics: Currently, 82 confirmed Ebola cases have been reported in Congo, with 7 deaths, 177 suspected deaths, and nearly 750 suspected cases, highlighting the severity and transmission potential of the outbreak.
- Uganda's Control Measures: Uganda has implemented measures such as intense contact tracing and cancellation of mass gatherings, which have effectively contained the virus's spread, despite two confirmed cases from Congo, one of which was fatal.
- Experimental Treatment Options: The WHO mentioned that Gilead Sciences' experimental antiviral drug Obeldesivir could be used among Ebola contacts for preventive treatment, although its implementation must follow very strict protocols, offering hope in the fight against the outbreak.
See More
Gilead Acquires Tubulis for $3.15B to Enhance Oncology Portfolio
- Acquisition Scale: Gilead Sciences completed the acquisition of Tubulis GmbH for $3.15 billion in upfront payments, with potential milestone payments of up to $1.85 billion, significantly enhancing its oncology portfolio through this strategic move.
- Innovation Center Establishment: Following the acquisition, the Tubulis team will remain in Munich to establish 'The Tubulis ADC Innovation Center,' focusing on research, manufacturing, and clinical development of antibody-drug conjugates, thereby enhancing Gilead's R&D capabilities in cancer treatment.
- Clinical Asset Integration: Tubulis' lead candidate TUB-040 is currently being evaluated for platinum-resistant ovarian and non-small cell lung cancers, and by integrating these clinical assets, Gilead aims to address significant treatment gaps for patients with challenging solid tumors.
- Market Leadership: This acquisition not only solidifies Gilead's leadership position in oncology innovation but also drives the advancement of transformative cancer treatments by combining existing infrastructure with Tubulis' innovative platform, addressing unmet medical needs.
See More
U.S. Stocks Rise as Hopes for Iran Peace Deal Increase
- Strong U.S. Market Performance: The S&P 500 rose by 0.4%, the Dow Jones increased by 0.6%, and the Nasdaq gained 0.2%, marking the longest weekly gain streak since 2023, indicating increased investor confidence in risk assets amid hopes for a U.S.-Iran peace deal.
- Active ETF Market: The SPDR S&P 500 ETF and Invesco QQQ Trust both rose by 0.4%, while the Dow Jones Industrial Average ETF increased by 0.7%, reflecting optimistic sentiment towards major indices, particularly ahead of the upcoming three-day weekend.
- Oil Prices Edge Up: International Brent crude futures added 0.9% to close at $103.54 per barrel, while West Texas Intermediate crude rose about 0.3%, reflecting market hopes for a resolution to the Iran conflict, although still below earlier peaks this week.
- New Fed Chair Sworn In: Kevin Warsh was officially sworn in as the 17th Chair of the Federal Reserve, with market expectations regarding his policy direction likely to influence future monetary policy and economic trends, especially in the context of the current economic recovery.
See More
Gilead Secures Accelerated Approval for Hepcludex
- FDA Accelerated Approval: Gilead Sciences' Hepcludex has received accelerated approval from the FDA, becoming the first treatment for chronic hepatitis delta virus infection in the U.S., addressing a long-standing gap in care for approximately 40,000 to 80,000 patients, which is expected to significantly enhance their quality of life.
- Clinical Trial Data Support: The FDA's decision was heavily informed by data from the MYR301 multi-center Phase 3 clinical trial, which demonstrated that the percentage of participants with completely undetectable viral levels increased from 20% at week 48 to 50% by week 144, confirming the drug's efficacy over time.
- Positive Market Reaction: Following the FDA approval, Gilead's stock price surged nearly 3%, poised for its best day in about three months, reflecting strong market anticipation for the new therapy and a recovery in investor confidence, with a 29% increase in stock price over the past year.
- Global Market Presence: While newly approved in the U.S., the 2 mg dose of Hepcludex has already been available in the European Economic Area and other global markets, indicating Gilead's strategic positioning and commitment to addressing chronic liver disease treatment worldwide.
See More
Gilead Receives FDA Approval for Chronic HDV Treatment
- FDA Accelerated Approval: Gilead Sciences announced that its Hepcludex (bulevirtide-gmod) 8.5 mg has received accelerated approval from the FDA, becoming the first treatment for chronic hepatitis delta virus (HDV) infection in the U.S., addressing a significant unmet medical need.
- Clinical Trial Results: In the pivotal MYR301 Phase 3 trial, Hepcludex demonstrated statistically significant improvements in HDV RNA reduction and alanine aminotransferase (ALT) normalization at Week 48 compared to the control group, indicating its efficacy.
- Patient Impact: Chronic HDV is considered the most severe form of viral hepatitis, and the FDA approval provides a new treatment option for approximately 40,000 to 80,000 HDV patients in the U.S., potentially significantly improving their quality of life and disease management.
- Future Research Commitment: Gilead has committed to conducting a confirmatory long-term outcomes study to verify the clinical benefits of Hepcludex, ensuring continued approval, which reflects the company's strong commitment to addressing this serious disease.
See More
FDA Approves Gilead's Hepcludex for HDV Infection
- First HDV Treatment: Gilead Sciences' Hepcludex (bulevirtide) has received FDA approval as the first-ever therapy for chronic hepatitis delta virus (HDV) infection, marking a significant breakthrough in liver disease treatment.
- Clinical Trial Success: The approval is based on phase 3 trial results showing that patients receiving Hepcludex had significantly better combined responses compared to those receiving delayed treatment, indicating its clinical efficacy.
- Special Drug Designations: Hepcludex has received Breakthrough Therapy and Orphan Drug designations, which not only expedited its approval process but also reflects the FDA's recognition of its potential in treating HDV infections.
- International Market Outlook: Approved in the EU in 2020 and expected to launch in Canada in 2025, Hepcludex demonstrates broad application potential in global markets, which could lead to substantial revenue growth for Gilead.
See More
WHO Raises Ebola Outbreak Risk Level in DRC to Very High
- Risk Level Increase: The WHO has raised the risk assessment for the Bundibugyo Ebola strain in the Democratic Republic of Congo to 'very high', indicating a significant potential for rapid virus spread that threatens national public health.
- Case Statistics: Currently, 82 confirmed Ebola cases have been reported in Congo, with 7 deaths, 177 suspected deaths, and nearly 750 suspected cases, highlighting the severity and transmission potential of the outbreak.
- Uganda's Control Measures: Uganda has implemented measures such as intense contact tracing and cancellation of mass gatherings, which have effectively contained the virus's spread, despite two confirmed cases from Congo, one of which was fatal.
- Experimental Treatment Options: The WHO mentioned that Gilead Sciences' experimental antiviral drug Obeldesivir could be used among Ebola contacts for preventive treatment, although its implementation must follow very strict protocols, offering hope in the fight against the outbreak.
See More
